Bristol-Myers Squibb's Cobenfy launch shows strong initial sales and growth potential. Learn why BMY stock is a solid ...

Bristol Myers Squibb's Breyanzi showed strong efficacy in Phase 2 lymphoma trial, meeting key endpoints. FDA approvals expand ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Bristol Myers Squibb Co. (BMY) on Thursday reported fourth-quarter earnings of $72 million. On a per-share basis, the Princeton, New Jersey-based ...

Despite a constantly changing global position, Business Editor Alan Healy reports on Ireland's enduring appeal as a location ...

Bristol Myers Squibb ... safety profile with no new safety signals. The study also met the key secondary endpoint of complete response rate. Bristol Myers Squibb said this study marks the fifth ...

Bristol Myers Squibb will cut $2 billion in costs by the ... allowing the company to invest in new drugs and research. The company previously outlined plans to cut $1.5 billion by 2025, which ...

For over 150 years, Bristol-Myers Squibb (BMS) has been committed to "discover, develop and deliver innovative medicines that help patients prevail over serious diseases." Headquartered in New ...

With another trial win, Bristol Myers Squibb is touting Breyanzi as the CD19 ... and there is a need for new effective and tolerable treatment options to address this unmet critical need ...

We recently published a list of 10 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Qorvo ...

As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), ...

In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE ... of repeatedly missing earnings estimates, a new CEO came in and now they’re knocking it out of ...